Vetigenics is focused on advancing targeted antibody-based therapies for pets with cancer and other chronic diseases. The company aims to transform personalized healthcare for pets while supporting advancements in human medicine, based on its proprietary CANIBODY™ platform.

Vetigenics

Corbiota develops natural animal health and welfare solutions that aim to improve productivity while meeting farmers' requirements. This is self-described as creating a new standard in animal nutrition.

Corbiota

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Dechra Pharmaceuticals PLC

HealthforAnimals represents the animal health sector: manufacturers of veterinary pharmaceuticals, vaccines and other animal health products throughout the world, as well as the associations that represent companies at national and regional levels.

Metric
Company Name	Vetigenics	Corbiota	Dechra Pharmaceuticals PLC	HealthforAnimals
Symbol			DPH
MSH ID	COM:VETIGENICS	COM:CORBIOTA	COM:DECHRA	ORG:HEALTHFORANIMALS
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Consumer Goods	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Animal Nutrition	Drug Manufacturers - General	Animal Health
Country	US	DE	GB	BE
Stage
Employee Count			2.46K
Website	vetigenics.com	corbiota.com	dechra.com	healthforanimals.org
LinkedIn
Founders

Metric
Market Cap	56.12M
Enterprise Value
Monthly Web Traffic		8.89K
Web Traffic Growth		0.68
Valuation
Raised Capital

Metric
Revenue			970.32M
Revenue (LTM)
Revenue (NTM)
Gross Profit			543.20M
EBITDA			125.00M
Operating Income			8.03M
Net Income			-35.55M
EPS			-0.32
Diluted EPS			-0.31
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.56
Operating Profit Margin			0.02
EBITDA Margin			0.13
Net Profit Margin			-0.04
Return on Equity			-0.03
Return on Assets			-0.02
Return on Capital Employed			0.01

COM:VETIGENICS

Vetigenics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-157.74
P/B Ratio			5.83
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			5.78
EV Multiple			63.88

Metric
Days Sales Outstanding
Days Payables Outstanding			158.91
Days Inventory Outstanding			238.97
Operating Cycle			308.09
Cash Conversion Cycle			149.18
Asset Turnover			0.49

Metric
Operating Cash Flow			81.04M
Free Cash Flow			42.43M
Cash Flow to Debt			0.13
Operating Cash Flow/Sales			0.08
Free Cash Flow Yield			0.01

Metric
Cash & Equivalents			94.80M
Accounts Receivable			-27.40M
Inventory			276.89M
Goodwill			426.23M
Debt to Capitalization			0.40
Debt to Assets			0.32
Current Ratio			2.85
Quick Ratio			1.33

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			-0.00
R&D to Revenue			0.12
SG&A to Revenue